Who are BP1001 plus decitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Decitabine and cedazuridine, Venetoclax-Decitabine/Azacitidine Association, Subcutaneous azacitidine, Tucidinostat, Azacitidine combined with CHOP, VEN combined with azacitidine, Decitabine plus HAAG regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bp1001-plus-decitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

BP1001 plus decitabine — Competitive Intelligence Brief

BP1001 plus decitabine (BP1001 plus decitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent. Area: Oncology.

phase 2 Hypomethylating agent DNA methyltransferase 1 (DNMT1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BP1001 plus decitabine (BP1001 plus decitabine) — Bio-Path Holdings, Inc.. Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1)

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BP1001 plus decitabine TARGET	BP1001 plus decitabine	Bio-Path Holdings, Inc.	phase 2	Hypomethylating agent	DNA methyltransferase 1 (DNMT1)
Decitabine and cedazuridine	Decitabine and cedazuridine	Race Oncology Ltd	marketed	Hypomethylating agent	DNA methyltransferase (DNMT)
Venetoclax-Decitabine/Azacitidine Association	Venetoclax-Decitabine/Azacitidine Association	The First Affiliated Hospital with Nanjing Medical University	phase 3	BCL-2 inhibitor/hypomethylating agent	BCL-2
Subcutaneous azacitidine	Subcutaneous azacitidine	Otsuka Australia Pharmaceutical Pty Ltd	phase 3	Hypomethylating agent	DNA methyltransferase
Tucidinostat, Azacitidine combined with CHOP	Tucidinostat, Azacitidine combined with CHOP	Peking Union Medical College Hospital	phase 3	Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen	Histone deacetylases, DNA methyltransferases
VEN combined with azacitidine	VEN combined with azacitidine	Nanfang Hospital, Southern Medical University	phase 3	Hypomethylating agent and histone deacetylase inhibitor	DNA methyltransferase and histone deacetylase
Decitabine plus HAAG regimen	Decitabine plus HAAG regimen	The First Affiliated Hospital of Soochow University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent class)

AbbVie (prior sponsor, Abbott) · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Bio-Path Holdings, Inc. · 1 drug in this class
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · 1 drug in this class
Otsuka Australia Pharmaceutical Pty Ltd · 1 drug in this class
Race Oncology Ltd · 1 drug in this class
Shirley Ryan AbilityLab · 1 drug in this class
Taiho Oncology, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BP1001 plus decitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/bp1001-plus-decitabine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab